ELCC 2016

Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.

Brigatinib demonstrated antitumor activity in crizotinib-treated and crizotinib-naïve patients with non-small cell lung cancer (NSCLC).

The addition of gefitinib to first-line pemetrexed plus carboplatin prolongs progression-free survival compared with chemotherapy alone and gefitinib alone.

Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.

BI 1482694 demonstrated meaningful clinical activity in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC).

Patients with clinically diagnosed early-stage lung cancer were found to have improved cancer-specific survival.

Afatinib significantly prolonged progression-free survival (PFS) for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).